Energy balance and obesity: the emerging role of glucagon like peptide-1 receptor agonists.

IF 3 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Current Opinion in Clinical Nutrition and Metabolic Care Pub Date : 2024-08-06 DOI:10.1097/MCO.0000000000001064

Noémie Beauregard, Kurt McInnis, Gary S Goldfield, Éric Doucet

{"title":"Energy balance and obesity: the emerging role of glucagon like peptide-1 receptor agonists.","authors":"Noémie Beauregard, Kurt McInnis, Gary S Goldfield, Éric Doucet","doi":"10.1097/MCO.0000000000001064","DOIUrl":null,"url":null,"abstract":"Purpose of review: With obesity affecting over one billion people globally, understanding and managing this complex condition is more crucial than ever. This review explores the emerging role of GLP-1 receptor agonists (GLP-1RA) in weight management, focusing on their impact on energy balance. It highlights the necessity of this investigation due to the limited knowledge on both the short-term and long-term implications of GLP-1RA on energy expenditure (EE) and energy intake (EI).Recent findings: GLP-1RA, such as liraglutide and semaglutide, have shown significant efficacy in promoting weight loss by reducing appetite, cravings and consequently, EI. Newer medications such as tirzepatide have demonstrated even greater weight loss success. Emerging evidence also suggests potential effects on EE, which could explain the greater weight loss success achieved with GLP-1 RA rather than typical lifestyle changes. However, comprehensive data on the total impact of these drugs on energy balance remain limited.Summary: The findings underscore the promising role of GLP-1RA in obesity management, particularly through mechanisms influencing both EI and EE. Future research should focus on systematically measuring all components of energy balance to fully elucidate the mechanisms of GLP-1RA and optimize their therapeutic use for personalized medicine.","PeriodicalId":10962,"journal":{"name":"Current Opinion in Clinical Nutrition and Metabolic Care","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Clinical Nutrition and Metabolic Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MCO.0000000000001064","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: With obesity affecting over one billion people globally, understanding and managing this complex condition is more crucial than ever. This review explores the emerging role of GLP-1 receptor agonists (GLP-1RA) in weight management, focusing on their impact on energy balance. It highlights the necessity of this investigation due to the limited knowledge on both the short-term and long-term implications of GLP-1RA on energy expenditure (EE) and energy intake (EI).

Recent findings: GLP-1RA, such as liraglutide and semaglutide, have shown significant efficacy in promoting weight loss by reducing appetite, cravings and consequently, EI. Newer medications such as tirzepatide have demonstrated even greater weight loss success. Emerging evidence also suggests potential effects on EE, which could explain the greater weight loss success achieved with GLP-1 RA rather than typical lifestyle changes. However, comprehensive data on the total impact of these drugs on energy balance remain limited.

Summary: The findings underscore the promising role of GLP-1RA in obesity management, particularly through mechanisms influencing both EI and EE. Future research should focus on systematically measuring all components of energy balance to fully elucidate the mechanisms of GLP-1RA and optimize their therapeutic use for personalized medicine.

查看原文本刊更多论文

能量平衡与肥胖症：胰高血糖素样肽-1 受体激动剂的新作用。

审查目的：全球有超过 10 亿人受到肥胖症的影响，因此了解和管理这一复杂的疾病比以往任何时候都更为重要。本综述探讨了 GLP-1 受体激动剂（GLP-1RA）在体重管理中的新作用，重点关注其对能量平衡的影响。由于对 GLP-1RA 对能量消耗（EE）和能量摄入（EI）的短期和长期影响了解有限，本综述强调了这一研究的必要性：最近的研究结果：GLP-1RA（如利拉鲁肽和司马鲁肽）通过降低食欲、欲望，进而降低能量摄入，在促进减肥方面显示出显著疗效。较新的药物，如替泽帕肽，在减轻体重方面取得了更大的成功。新的证据还表明，GLP-1 RA 对 EE 有潜在的影响，这也可以解释为什么使用 GLP-1 RA 比改变一般的生活方式能取得更大的减肥效果。小结：研究结果表明，GLP-1RA 在肥胖控制中的作用前景广阔，尤其是通过影响 EI 和 EE 的机制。未来的研究应侧重于系统测量能量平衡的所有组成部分，以全面阐明 GLP-1RA 的作用机制，并优化其在个性化医疗中的治疗应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Clinical Nutrition and Metabolic Care 医学-内分泌学与代谢

CiteScore

5.30

自引率

6.50%

发文量

116

审稿时长

6-12 weeks

期刊介绍： A high impact review journal which boasts an international readership, Current Opinion in Clinical Nutrition and Metabolic Care offers a broad-based perspective on the most recent and exciting developments within the field of clinical nutrition and metabolic care. Published bimonthly, each issue features insightful editorials and high quality invited reviews covering two or three key disciplines which include protein, amino acid metabolism and therapy, lipid metabolism and therapy, nutrition and the intensive care unit and carbohydrates. Each discipline introduces world renowned guest editors to ensure the journal is at the forefront of knowledge development and delivers balanced, expert assessments of advances from the previous year.

文献相关原料

公司名称	产品信息	采购帮参考价格